You just read:

Phase III Select Trial of Lenvatinib Meets Primary Endpoint of Improved Progression Free Survival in the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

News provided by

Eisai Europe Limited

03 Feb, 2014, 09:09 GMT